Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310907 | 0.90 | TLR7 (0.55) | TLR7KDM4ETLR8ACSS2RAB9A | |
| SCHEMBL21310908 | 0.86 | RPS6KA5 (0.49) | TLR7KDM4ETLR8ADORA2ACNR2 | |
| SCHEMBL22725496 | 0.84 | KDM4E (0.56) | TLR7KDM4ETLR8PTGER4EHMT2 | |
| SCHEMBL22121391 | 0.82 | KDM4E (0.60) | TLR7KDM4EPTGER4EHMT2ITK | |
| SCHEMBL2362229 | 0.81 | KDM4E (0.58) | TLR7KDM4EPTGER4EHMT2ITK | |
| SCHEMBL21310917 | 0.81 | EGFR (0.54) | TLR7ITKADORA2ARAB9A | |
| SCHEMBL6270717 | 0.80 | ALDH1A1 (0.61) | TLR7TLR8ACSS2ADORA2A | |
| SCHEMBL19436514 | 0.80 | KDM4E (0.56) | KDM4ETLR8PTGER4EHMT2ITK | |
| SCHEMBL6420487 | 0.79 | KDM4E (0.50) | TLR7KDM4ETLR8ACSS2CNR2 | |
| Bromide SCHEMBL23227960 | 0.79 | KDM4E (0.55) | KDM4ETLR8PTGER4EHMT2ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | TLR7 4378/4885KDM4E 2662/4885TLR8 3372/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | TLR7 4241/4885KDM4E 2411/4885TLR8 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.